Table 1. Cytotoxicity of the Investigated Platinum(IV) Complexes in Comparison with the Clinically Applied Platinum(II) Drugs in the CH1 and SW480 Human Cancer Cell Lines.
IC50 (μM)a |
IC50 (μM)a |
||||
---|---|---|---|---|---|
compd | CH1 | SW480 | compd | CH1 | SW480 |
1 | 19 ± 1 | 136 ± 16 | 30 | 24 ± 5 | >500 |
2 | 0.62 ± 0.32 | 3.8 ± 1.0 | 31 | 8.6 ± 1.7 | 350 ± 39 |
3 | 28 ± 2 | 183 ± 28 | 32 | 11 ± 6 | 181 ± 44 |
4 | 12 ± 4 | 48 ± 4 | 33 | 62 ± 26 | >500 |
5 | 1.9 ± 0.2 | 24 ± 4 | 34 | 44 ± 8 | >500 |
6 | 5.5 ± 2.2 | 95 ± 5 | 35 | 15 ± 5 | >500 |
7 | 0.68 ± 0.20 | 16 ± 1 | 36 | 28 ± 2 | >500 |
8 | 0.34 ± 0.11 | 4.1 ± 0.5 | 37 | 31 ± 13 | >500 |
9 | 0.068 ± 0.024 | 0.63 ± 0.20 | 38 | 114 ± 23 | >500 |
10 | 0.018 ± 0.007 | 0.22 ± 0.08 | 39 | 33 ± 13 | >500 |
11 | 24 ± 3 | 142 ± 23 | 40 | 7.7 ± 1.4 | >250 |
12 | 2.3 ± 1.1 | 31 ± 15 | 41 | 89 ± 7 | >500 |
13 | 1.9 ± 0.2 | 19 ± 9 | 42 | 128 ± 48 | >500 |
14 | 32 ± 19 | 160 ± 10 | 43 | 23 ± 9 | >500 |
15 | 1.1 ± 0.2 | 3.5 ± 0.1 | 44 | 49 ± 13 | >500 |
16 | 21 ± 8 | 90 ± 21 | 45 | 125 ± 35 | >500 |
17 | 22 ± 12 | 43 ± 22 | 46 | 22 ± 8 | >500 |
18 | 7.8 ± 1.0 | 21 ± 5 | 47 | 33 ± 4 | >500 |
19 | 0.17 ± 0.05 | 2.9 ± 1.0 | 48 | 21 ± 6 | >500 |
20 | 0.055 ± 0.006 | 0.96 ± 0.4 | 49 | 1.9 ± 0.3 | 100 ± 6 |
21 | 5.6 ± 1.6 | 40 ± 12 | 50 | 2.1 ± 0.3 | 161 ± 33 |
22 | 0.16 ± 0.05 | 1.0 ± 0.3 | 51 | 55 ± 28 | 44 ± 9 |
23 | 0.061 ± 0.015 | 0.30 ± 0.05 | 52 | 19 ± 5 | 14 ± 3 |
24 | 0.014 ± 0.002 | 0.11 ± 0.01 | 53 | 11 ± 2 | 12 ± 5 |
25 | 0.0094 ± 0.0012 | 0.39 ± 0.07 | cisplatin | 0.16 ± 0.03 | 3.50 ± 0.29 |
26 | 0.75 ± 0.10 | 6.1 ± 0.6 | carboplatin | 1.36 ± 0.40 | 85 ± 28 |
27 | 171 ± 1 | >500 | oxaliplatinb | 0.33 ± 0.09 | 0.30 ± 0.08 |
28 | 32 ± 10 | >500 | nedaplatin | 0.14 ± 0.05 | 6.3 ± 1.3 |
29 | 28 ± 4 | >500 |
The reported 50% inhibitory concentrations are the means ± standard deviations obtained from three independent experiments.
Data taken from ref (24).